{"id":83362,"date":"2026-05-15T16:25:12","date_gmt":"2026-05-15T16:25:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/83362\/"},"modified":"2026-05-15T16:25:12","modified_gmt":"2026-05-15T16:25:12","slug":"buy-sell-or-hold-novo-nordisk-at-46-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/83362\/","title":{"rendered":"Buy, Sell, or Hold Novo Nordisk at $46?"},"content":{"rendered":"

Novo Nordisk (NYSE: NVO) shares have continued their underperformance — losing 7.5% so far this year compared to the S&P 500 index’s 8% gain.<\/p>\n

Of course, that’s in the past. Current and potential Novo Nordisk shareholders<\/a> want to know what to do now, with the stock price at about $46. To make that determination, you need to look closer at Novo Nordisk’s fundamentals.<\/p>\n

Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue \u00bb<\/a><\/p>\n

\"Someone<\/p>\n

Image source: Getty Images.<\/p>\n

Analyzing the fundamentals<\/p>\n

Novo Nordisk makes Wegovy and Ozempic, popular weight loss and diabetes treatments. They’re a major source of the company’s sales. Weight loss and diabetes treatments made up more than three-quarters of the company’s first-quarter sales, with Wegovy and Ozempic comprising the majority. Many people have heard about the drugs, and likely know someone taking, or considering, taking them.<\/p>\n

While these drugs have caught on with people, there have been signs that Wegovy and Ozempic have been affected by competition. For instance, the latter’s first-quarter sales dropped 8% year over year on a constant-currency basis. True, Novo Nordisk began selling a Wegovy pill, but Eli Lilly(NYSE: LLY) also received FDA approval for an oral treatment, Foundayo.<\/p>\n

Aside from Eli Lilly, Novo Nordisk also faces stiff competition from other companies. That includes Pfizer, which acquired Metsera in November based on its weight-loss drug pipeline.<\/p>\n

Certainly, obesity and diabetes have been ongoing problems for many people. Hence, companies want to enter it to get a piece of the market. Certainly, Novo Nordisk doesn’t have it all to itself. With intense competition and the company’s reliance on the drug treatments for the bulk of its sales, I’d sell Novo Nordisk shares.<\/p>\n

Should you buy stock in Novo Nordisk right now?<\/p>\n

Before you buy stock in Novo Nordisk, consider this:<\/p>\n

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n

Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you\u2019d have $468,861!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you\u2019d have $1,445,212!*<\/p>\n

Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 1,013% \u2014 a market-crushing outperformance compared to 210% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n

See the 10 stocks \u00bb<\/a><\/p>\n

*Stock Advisor returns as of May 15, 2026. <\/p>\n

Lawrence Rothman, CFA<\/a> has positions in Pfizer. The Motley Fool has positions in and recommends Eli Lilly and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy<\/a>.<\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NYSE: NVO) shares have continued their underperformance — losing 7.5% so far this year compared to…\n","protected":false},"author":2,"featured_media":83363,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[5921,5918,5917,5920,5919,5922,272,3858,3859,4011],"class_list":{"0":"post-83362","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-futures","9":"tag-index-market-quote","10":"tag-index-market-quotes","11":"tag-index-market-symbol","12":"tag-index-market-symbols","13":"tag-indices","14":"tag-novo-nordisk","15":"tag-novo-nordisk-a-s-adr","16":"tag-nvo","17":"tag-the-globe-and-mail"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116579528082628529","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/83362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=83362"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/83362\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/83363"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=83362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=83362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=83362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}